SUPPLEMENTAL MATERIAL

S1. Patient characteristics according to LVH etiology

Characteristic	Amyloidosis		Sarcomeric HCM		Hypertensive CMP		Undetermined		Other	
Age (y)	79	[70 – 84]	59	[49 – 68]	64	[51 – 74]	74	[61 – 81]	58	[45.7 – 71.3]
Female, N (%)	41	(20.2%)	76	(40.0%)	40	(31.2%)	11	(24.4%)	10	(40.0%)
BMI (kg/m²)	25.1	[22.8 – 27.7]	26.1	[22.8 – 30.1]	27.4	[24.4 – 29.8]	28.7	[23.6 – 32.0]	23.7	[20.3 – 28.1]
BSA (m²)	1.85	[1.74 – 1.93]	1.86	[1.69 – 2.00]	1.87	[1.74 – 2.01]	1.94	[1.74 – 2.07]	1.86	[1.57 – 1.97]
Arterial hypertension, N (%)	103	(50.7%)	96	(5.5%)	128	(100%)	31	(68.9%)	14	(56.0%)
Neuromuscular disorder, N (%)	97	(47.8%)	7	(3.7%)	6	(4.7%)	5	(11.1%)	2	(8.0%)
NYHA class	2	[2 – 3]	2	[1 – 2]	2	[1 – 2]	2	[1 – 3]	2	[1 – 2]
Electrical hypertrophy , N (%)	13	(6.4%)	70	(36.8%)	33	(25.8%)	9	(20.0%)	7	(28.0%)
Conduction disorder or PPM, N (%)	139	(68.8%)	84	(44.2%)	45	(35.2%)	19	(42.2%)	17	(68.0%)
Ventricular arrhythmia or ICD, N (%)	7	(3.5%)	29	(15.3%)	2	(1.6%)	2	(4.4%)	7	(28.0%)

S1. Transthoracic echocardiography findings according to LVH etiology

Characteristic	Amyloidosis		Sarcomeric HCM		Hypertensive CMP		Undetermined		Other	
Maximal LVWT (mm)	15	[14 – 18]	16	[14 – 18]	14	[13 – 16]	14	[13 – 16]	13	[12 – 15]
Indexed LV mass (g/m²)	131	[112 – 156]	115	[92 – 146]	128	[103 – 154]	116	[97 – 157]	140	[109 – 171]
Indexed LA volume (ml/m²)	48	[39 – 57]	46	[34 – 59]	44	[30 – 55]	47	[35 – 67]	37	[24 – 59]
LVEF (%)	50	[41 – 58]	62	[56 – 68]	59	[48 – 65]	59	[52 – 63]	55	[38 – 63]
LV GLS (%)	-11.0	[-13.3 – -8.8]	-15.1	[-18.3 – -11.8]	-14.8	[-17.9 – -10.9]	-16.5	[-18.1 – -12.7]	-14.5	[-16.4 – -10.2]
TAPSE (mm)	16	[13 – 19]	21	[18 – 24]	21	[18 – 25]	20	[16 – 22]	19	[16 – 24]
S'T (cm/s)	10.0	[8.0 – 12.0]	13.0	[11.0 – 15.0]	12.0	[10.0 – 14.0]	12.0	[9.2 – 14.8]	13.0	[8.0 – 14.6]

Abbreviations as in Table 1.

Abbreviations as in Table 2.

S3. Distribution of cardiac amyloidosis etiologies

Subtypes of amyloidosis	N	(%)
All ATTR	154	(75.9)
Inherited ATTR	*26*	*(12.8)*
Wild-type ATTR	*93*	*(45.8)*
Undetermined ATTR	*35*	*(17.2)*
AL	45	(22.2)
Other	4	(2.0)

AL: light-chain amyloidosis, ATTR: transthyretin amyloidosis, Undetermined ATTR corresponds to patients who were not able to consent to or declined genetic screening.

S4. Sarcomere gene testing and distribution of mutations

Genetics in sarcomeric HCM	N	(%)	(% of mutated)
Untested	56	(29.6)	*(NA)*
MYBPC3 mutation	20	(10.5)	(50.0)
MYH7 mutation	15	(7.9)	(37.5)
TNNI3 mutation	1	(0.5)	(2.5)
MYL2 mutation	2	(1.1)	(5.0)
TNNT2 mutation	2	(1.1)	(5.0)
No known mutation	71	(37.4)	*(NA)*
Pending or unknown results	23	(12.1)	*(NA)*

MYBPC3: myosin binding protein 3, MYH7: myosin heavy chain 3, MYL2: myosin regulatory light chain 2, TNNI3: troponin I 3, TNNT2: troponin T 2.